Pharmaceuticals

Adalimumab, Infliximab and Etanercept Biosimilars Market Size Forecast To Achieve $8.04 Billion By 2030 With 10.1% CAGR

May 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Adalimumab, Infliximab and Etanercept Biosimilars Market During The Forecast Period?

The market size for adalimumab, infliximab, and etanercept biosimilars has shown rapid development in recent years. It is forecast to increase from $4.96 billion in 2025 to $5.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The expansion observed historically can be linked to the rising occurrence of autoimmune diseases, the substantial cost of originator biologics, growing understanding of biosimilars, enhancements in biologics manufacturing, and supportive governmental policies.

The adalimumab, infliximab and etanercept biosimilars market size is anticipated to undergo significant expansion over the coming years. It is projected to reach $8.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. This expansion during the forecast period is propelled by factors such as advancements in precision medicine, the growing scope of biosimilar pipelines, increasing healthcare expenditure, wider adoption of digital health solutions, and an expanding geriatric population. Prominent trends expected in this timeframe encompass biosimilar adoption and market penetration, the development of cost-effective tnf-alpha inhibitors, favorable regulatory approvals and policy support, the expansion of hospital and retail pharmacy networks, and the implementation of personalized treatment protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Which Drivers Are Advancing The Adalimumab, Infliximab and Etanercept Biosimilars Market Growth?

The increasing occurrence of autoimmune conditions is anticipated to drive the expansion of the adalimumab, infliximab, and etanercept biosimilars market in the future. An autoimmune disease is characterized by disorders or sicknesses resulting from an immune system malfunction, where immune cells target and attack the body’s own healthy cells. Adalimumab, infliximab, and etanercept are biological medications, specifically tumor necrosis factor (TNF) alpha inhibitors, employed in the treatment of diverse autoimmune ailments. As an illustration, data from Johns Hopkins University, a private research university located in the US, indicated that approximately 10 million individuals in the US, representing 3% of the populace, were impacted by autoimmune illnesses in 2023. Consequently, the growing frequency of autoimmune diseases is a key factor boosting the growth of the adalimumab, infliximab, and etanercept biosimilars market.

How Is The Adalimumab, Infliximab and Etanercept Biosimilars Market Distributed Across Key Segments?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Which Trends Are Guiding The Development Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Leading companies operating within the adalimumab, infliximab, and etanercept biosimilars market are concentrating on technological improvements, such as high-concentration, citrate-free biosimilars, to address the growing demand for formulations that are easier for patients to use, more economical, and have wider market access. These advanced high-concentration, citrate-free versions provide the same therapeutic monoclonal antibody structure as traditional biosimilars but ensure a more comfortable injection experience, reducing the sting upon administration, which may lead to better adherence and higher switching rates compared to standard buffered formulations. For example, in June 2023, Celltrion USA, a US-based biopharmaceutical company, unveiled Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab), engineered to offer equivalent potency and efficacy in a format more accommodating for patients. Yuflyma delivers the full therapeutic effect of adalimumab, with the added benefit of enhanced tolerability due to reduced injection pain, and promotes wider acceptance in the immunology market, especially for chronic inflammatory diseases.

Which Key Players Are Active In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad

Access The Complete Adalimumab, Infliximab and Etanercept Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Region Accounts For The Highest Share Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Adalimumab, Infliximab and Etanercept Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795